10-Q: Guided Therapeutics Q2 Loss Widens, Liquidity Concerns Persist

Guided Therapeutics reported a widened net loss and deepening accumulated deficit in Q2 2025, highlighting significant liquidity challenges despite progress in regulatory approvals for its LuViva device.

Summary

• Net loss attributable to common stockholders increased to $1.32 million for the six months ended June 30, 2025, up from $1.20 million in the prior year.
• Sales of devices and disposables significantly increased to $117,462 for the six months ended June 30, 2025, compared to $5,720 in the same period of 2024.
• The company reported negative working capital of approximately $5.6 million and an accumulated deficit of $155.0 million as of June 30, 2025.
• Cash and cash equivalents decreased to $185,000 at June 30, 2025, from $388,000 at December 31, 2024.
• Net cash used in operating activities increased to $500,000 for the six months ended June 30, 2025, from $314,000 in the prior year.
• The company raised $205,000 from a private placement offering and $355,250 from new notes payable during the six months ended June 30, 2025.
• Common stock outstanding increased to 78,971,323 shares at June 30, 2025, from 65,130,623 shares at December 31, 2024, indicating significant dilution.
• The company's 10% Senior Unsecured Convertible Debenture of $1.13 million is in default, accruing interest at 18%.
• US FDA clinical trial for LuViva has surpassed minimum enrollment, with data analysis initiated as of August 1, 2025.
• China NMPA application for LuViva was accepted and is under review, with a mandatory manufacturing site inspection scheduled for October 2025.
• Full approval to market and sell LuViva in Russia was granted as of August 11, 2025.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, including negative working capital, increasing accumulated deficit, and significant cash burn, raising substantial doubt about its going concern ability. While there's some operational progress in clinical trials and regulatory approvals, the financial situation is critical and debt defaults are present. The capital raises are short-term fixes that come with significant dilution.

Positives

• Sales of LuViva devices and disposables increased significantly to $117,462 for the six months ended June 30, 2025, compared to $5,720 in the prior year.
• Gross profit improved to $79,250 for the six months ended June 30, 2025, from $3,845 in the prior year.
• US FDA clinical trial for LuViva has surpassed minimum enrolled subjects (approximately 430 patients as of August 1, 2025), with data analysis underway and no adverse events reported.
• China NMPA application for LuViva was accepted and is under review, with clinical results showing 83% sensitivity and 54% specificity, exceeding NMPA requirements.
• Full regulatory approval to market and sell LuViva in Russia was granted as of August 11, 2025.
• Secured new purchase orders from Turkey and Indonesia, expected to generate approximately $200,000 in revenue for 2025.
• Received $204,500 from a private placement offering and $355,250 from new notes payable, providing some capital inflow.
• Recognized a gain of $83,260 from the change in fair value of derivative liability for the six months ended June 30, 2025.
• Recognized $180,000 in other income from deferred revenue related to an agreement with SMI and $52,400 from the Employee Retention Credit program.

Negatives

• Net loss attributable to common stockholders widened to $1.32 million for the six months ended June 30, 2025, from $1.20 million in the prior year.
• Accumulated deficit increased to $155.0 million as of June 30, 2025.
• Negative working capital worsened to approximately $5.6 million at June 30, 2025.
• Cash and cash equivalents decreased to $185,000 at June 30, 2025, from $388,000 at December 31, 2024.
• Net cash used in operating activities increased to $500,000 for the six months ended June 30, 2025, from $314,000 in the prior year.
• General and administrative expenses significantly increased by 54.1% to $925,032 for the six months ended June 30, 2025, primarily due to a one-time $270,389 charge for CEO warrants.
• Interest expense more than doubled to $303,448 for the six months ended June 30, 2025, from $139,490 in the prior year.
• The $1.13 million 10% Senior Unsecured Convertible Debenture is in default and accruing interest at 18%.
• A related party note held by Dr. Gene Cartwright for $309,111 was overdue as of June 30, 2025.
• SMI, a Chinese partner, is in contractual default due to $200,000 in late payments and failure to provide data.
• Significant dilution occurred with common stock outstanding increasing by over 13.8 million shares since December 31, 2024.
• Incurred a $31,928 loss from extinguishment of debt related to exchange agreements.

Risks

• Inability to access sufficient debt or equity capital to meet operating and financial needs.
• Significant dilution of existing stockholders' holdings upon issuance, conversion, or exercise of securities from capital raising efforts.
• Risk that certain debt holders may call notes for immediate payment.
• Uncertainty regarding the effectiveness and ultimate market acceptance of products and ability to generate sufficient sales revenues.
• Uncertainty whether products in development will prove safe, feasible, and effective.
• Inability to obtain required regulatory approvals (e.g., FDA, NMPA) in a timely manner or at all.
• Challenges in achieving manufacturing scale-up and efficient manufacturing of sufficient product quantities.
• Lack of immediate alternate sources of supply for some critical components.
• Inability to establish and protect proprietary information, patents, and intellectual property.
• Impact of geopolitical conflicts (e.g., Russia-Ukraine) on operations and regulatory approvals.
• Potential adverse effects on operations, supply chain, and cost structure from tariffs, trade restrictions, or other international trade policies.
• Need to fully develop marketing, distribution, customer service, and technical support functions.
• Dependence on potential strategic partners or outside investors for funding, development assistance, clinical trials, distribution, and marketing.
• Material weaknesses in internal control over financial reporting due to lack of resources for complex transactions and insufficient oversight/approval of significant transactions.

Future Outlook

The company expects operating losses to continue for the foreseeable future as it expends substantial resources on product commercialization, regulatory clearances, and building marketing, sales, manufacturing, and finance capabilities. It anticipates needing approximately $2.3 million to fund operations over the next 12 months, with additional manufacturing expenditures contingent on customer orders and advance payments. The US FDA clinical trial is expected to be completed in 2025, and NMPA approval in China is projected for later this year, following a mandatory manufacturing site inspection in October 2025. The company aims to generate approximately $2.0 million in additional sales within the next twelve months, contingent on Chinese regulatory approval, and expects $200,000 in revenue from Turkey and Indonesia orders in 2025.

Management Comments

• We expect our operating losses to continue for the foreseeable future as we continue to expend substantial resources to complete commercialization of our products, obtain regulatory clearances or approvals, build our marketing, sales, manufacturing and finance capabilities, and conduct further research and development.
• We currently hold and expect to generate additional purchase orders which we expect to result in actual sales of approximately $2.0 million within the next twelve months.
• As of August 1, 2025, approximately 430 patients have been enrolled and tested [in the US FDA clinical trial], which is above the target minimum number needed to file the application with the FDA.
• There have not been any adverse events reported related to the use of LuViva [in the US FDA clinical trial].
• SMI has informed us that a mandatory inspection of their manufacturing site has been scheduled for October of 2025, which is consistent with NMPA approval later this year.
• On August 11, 2025, we were informed by Newmars that full approval to market and sell LuViva in Russia had at last been granted.
• The current plan involves a collaboration with MOH [Turkish Ministry of Health] to conduct a clinical study in Turkey to support the use of LuViva for primary screening of cervical cancer as a replacement for the Pap test under the public health system. The MOH has informed us that this would potentially involve up to 20 million tests annually in Turkey paid for by the Turkish national healthcare system.
• We estimate that approximately $2.3 million will be needed to fund the business over the next 12 months.

Industry Context

The company operates in the highly competitive and rapidly changing medical device industry, specifically focusing on biophotonics technology for non-invasive cancer detection. This sector is characterized by significant R&D expenditures, stringent regulatory approval processes (e.g., FDA, NMPA), and the need for substantial sales and marketing infrastructure. The company's strategy of targeting both developed markets (triage after traditional screening) and developing markets (primary screening where infrastructure is limited) positions it within a global healthcare context, but also exposes it to diverse regulatory and commercialization challenges. Geopolitical factors, such as the conflict in Ukraine and international tariffs, add further complexity to market access and supply chain stability.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks.
• The company's continued net losses and accumulated deficit are indicative of a pre-profit or early-commercialization stage common in the medical device industry, which typically requires significant upfront investment in R&D and regulatory processes before achieving widespread market adoption and profitability.
• The reported clinical trial results (83% sensitivity, 54% specificity for NMPA) are presented as 'better than required by NMPA,' suggesting a positive technical outcome relative to regulatory thresholds, but without broader industry benchmarks for similar devices, a comprehensive comparative assessment is limited.

Management Changes

Corporate Governance

Legal Proceedings

• No accrual recorded for any potential losses related to pending litigation as of June 30, 2025, and December 31, 2024.
• Management believes dispositions of matters are not expected to have a material adverse effect on financial condition, but an unfavorable resolution could materially affect future results.

Related Party Transactions

• Private placement offering on March 18, 2025, included participation from John Imhoff and Michael James, members of the Board of Directors, who exchanged $50,000 in notes payable and accrued interest for common stock and warrants.
• Revised compensation agreement for CEO Dr. Mark Faupel approved on June 3, 2025, including warrants and deferred salary.
• Promissory notes held by Dr. Mark Faupel ($193,264 outstanding as of June 30, 2025) and Dr. Gene Cartwright ($309,111 outstanding and overdue as of June 30, 2025).
• Royalty agreement with director John Imhoff and stockholder Dolores Maloof for future sales of cervical guides ($0.20 per guide).
• Consulting agreement with Richard Blumberg (director) involving warrants and common stock shares, with nil unrecognized expense as of June 30, 2025.
• Consulting agreement with Ironstone Capital Corp. (extended through January 31, 2026), which includes Alan Grujic (Compensation Committee Member).

Stakeholder Impact

• Shareholders: Significant dilution from recent and potential future equity issuances (e.g., private placement, convertible debt conversions, CEO compensation warrants). Continued net losses and accumulated deficit erode shareholder equity.
• Employees: Potential for increased headcount to meet manufacturing demand, but also risk of curtailing operations and staffing reductions if capital cannot be raised. CEO's compensation package includes deferred salary and performance-based warrants.
• Customers: Potential for increased product availability (LuViva devices and disposables) with regulatory approvals and new orders, but also risk of supply chain issues and delays in product delivery if manufacturing capacity or parts are constrained.
• Suppliers: Increased demand for parts and services for production, but potential for payment delays or reduced orders if the company faces further liquidity challenges.
• Creditors: Several debt obligations are in default or overdue, indicating increased risk for creditors. Convertible notes with variable conversion prices and default provisions could lead to complex repayment scenarios.

Next Steps

• Complete and file the US FDA study results (estimated $425,000 additional expenditure).
• Undergo mandatory NMPA manufacturing site inspection in October 2025 for Chinese regulatory approval.
• Ship devices to HDMT (first three expected this quarter, subsequent over seven months).
• Ship four devices to Indonesia in Q3 2025.
• Conduct a clinical study in Turkey (approx. 800 patients, <6 months, MOH funded) to support LuViva's use for primary screening.
• Continue efforts to raise additional capital to fund operations and regulatory processes.
• Remediate material weaknesses in internal control over financial reporting.
• Address contractual defaults with SMI.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by a substantial accumulated deficit, negative working capital, and a 'going concern' warning. While there are positive developments in regulatory approvals and sales growth, these are overshadowed by increasing net losses, significant cash burn from operations, and a heavy debt load, including multiple defaults. The reliance on dilutive capital raises and the material weaknesses in internal controls further exacerbate the risk profile. The long-term viability is highly questionable without a dramatic and sustained improvement in financial performance and capital structure, making it a high-risk investment with significant downside potential.

Keywords

Medical Device, Cervical Cancer Screening, LuViva, Biophotonics, FDA Approval, NMPA Approval, Convertible Debt, Going Concern, Capital Raise, Healthcare Technology, Diagnostics, SEC Filing, GTII